Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1302-1308

  Chattopadhyay, Mitali ^a   Nath, Niharika ^b   Kodela, Ravinder ^a   Sobocki, Tomasz ^a   Metkar, Shalaka ^a   Gan, Zong Yuan ^a   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Catenin; Apoptosis; Caspase 3; Cell cycle; Hydrogen sulfide; Leukemia; Proliferation

Indexed keywords

4 (5 THIOXO 5H 1, 2 DITHIOL 3 YL)PHENYL 2 ACETOXYBENZOATE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BETA CATENIN; BORTEZOMIB; CASPASE 3; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ANALYSIS;

Β-CATENIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ALL; APOPTOSIS; ASA; ASPIRIN; CASPASE-3; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CML; HS-ASA; HYDROGEN SULFIDE; HYDROGEN SULFIDE-RELEASING ASPIRIN; LEUKEMIA; NITRIC OXIDE; NO; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; PROLIFERATION;

ASPIRIN; BETA CATENIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN SULFIDE; JURKAT CELLS;

EID: 84883553253     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.004     Document Type: Article

References (33)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Bartram C.R., Schrauder A., Kohler R., Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arztebl Int 2012, 109:652-658.
3. Hu Y., Chen Y., Douglas L., Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23:109-116.
4. Chung E.J., Hwang S.G., Nguyen P., Lee S., Kim J.S., Kim J.W., et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002, 100:982-990.
5. Rothwell P.M., Price J.F., Fowkes F.G., Zanchetti A., Roncaglioni M.C., Tognoni G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612.
6. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601.
7. Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol 2009, 57:31-89.
8. Li L., Rossoni G., Sparatore A., Lee L.C., Del Soldato P., Moore P.K. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007, 42:706-719.
9. Sparatore A., Santus G., Giustarini D., Rossi R., Del Soldato P. Therapeutic potential of new hydrogen sulfide-releasing hybrids. Expert Rev Clin Pharmacol 2011, 4:109-121.
10. Lazzarato L., Chegaev K., Marini E., Rolando B., Borretto E., Guglielmo S., et al. New nitric oxide or hydrogen sulfide releasing aspirins. J Med Chem 2011, 54:5478-5484.
11. Kashfi K., Olson K.R. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol 2013, 85:689-703.
12. Chattopadhyay M., Kodela R., Nath N., Barsegian A., Boring D., Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol 2012, 83:723-732.
13. Chattopadhyay M., Kodela R., Nath N., Dastagirzada Y.M., Velazquez-Martinez C.A., Boring D., et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol 2012, 83:715-722.
14. Chattopadhyay M., Kodela R., Nath N., Street C.R., Velazquez-Martinez C.A., Boring D., et al. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol 2012, 83:733-740.
15. Wallace J.L., Caliendo G., Santagada V., Cirino G., Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132:261-271.
16. Wallace J.L., Dicay M., McKnight W., Martin G.R. Hydrogen sulfide enhances ulcer healing in rats. FASEB J 2007, 21:4070-4076.
17. Tsutsui J., Moriyama M., Arima N., Ohtsubo H., Tanaka H., Ozawa M. Expression of cadherin-catenin complexes in human leukemia cell lines. J Biochem 1996, 120:1034-1039.
18. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
19. Dillard A.C., Lane M.A. Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog 2007, 46:315-329.
20. Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007, 8:R19.
21. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
22. Chapple K.S., Cartwright E.J., Hawcroft G., Tisbury A., Bonifer C., Scott N., et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000, 156:545-553.
23. Bellosillo B., Pique M., Barragan M., Castano E., Villamor N., Colomer D., et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998, 92:1406-1414.
24. Nath N., Labaze G., Rigas B., Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun 2005, 326:93-99.
25. Lu Y., Chen G.Q. Effector caspases and leukemia. Int J Cell Biol 2011, 2011:738301.
26. Razavi R., Gehrke I., Gandhirajan R.K., Poll-Wolbeck S.J., Hallek M., Kreuzer K.A. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res 2011, 17:286-293.
27. Lin Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000, 97:4262-4266.
28. Dihlmann S., Siermann A., von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001, 20:645-653.
29. Webb S.J., Nicholson D., Bubb V.J., Wyllie A.H. Caspase-mediated cleavage of APC results in an amino-terminal fragment with an intact armadillo repeat domain. FASEB J 1999, 13:339-346.
30. Steinhusen U., Badock V., Bauer A., Behrens J., Wittman-Liebold B., Dorken B., et al. Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 2000, 275:16345-16353.
31. Van de Craen M., Berx G., Van den Brande I., Fiers W., Declercq W., Vandenabeele P. Proteolytic cleavage of beta-catenin by caspases: an in vitro analysis. FEBS Lett 1999, 458:167-170.
32. Weinberg J.B. Nitric oxide and life or death of human leukemia cells. Cancer drug discovery and development nitric oxide (NO) and cancer prognosis, prevention, and therapy 2010, 147-167. Springer Science+Business Media, LLC, New York. 10.1007/978-1-4419-1432-3. B. Bonavida (Ed.).
33. Predmore B.L., Lefer D.J., Gojon G. Hydrogen sulfide in biochemistry and medicine. Antioxid Redox Signal 2012, 17:119-140.